Citation: | BAI Min, HUANG Lieping, ZHU Bei, WU Jinhua, WU Qiong, HONG Kaiting, YU Youna. Mediating effect of leptin levels between insulin resistance and nonalcoholic fatty liver disease in obese children[J]. Chinese Journal of General Practice, 2023, 21(12): 2086-2088. doi: 10.16766/j.cnki.issn.1674-4152.003296 |
[1] |
POWELL E E, WONG V W, RINELLA M. Non-alcoholic fatty liver disease[J]. Lancet, 2021, 397(10290): 2212-2224. doi: 10.1016/S0140-6736(20)32511-3
|
[2] |
BRUNNER K T, HENNEBERG C J, WILECHANSKY R M, et al. Nonalcoholic fatty liver disease and obesity treatment[J]. Curr Obes Rep, 2019, 8(3): 220-228. doi: 10.1007/s13679-019-00345-1
|
[3] |
FRIEDMAN S L, NEUSCHWANDER-TETRI B A, RINELLA M, et al. Mechanisms of NAFLD development and therapeutic strategies[J]. Nat Med, 2018, 24(7): 908-922. doi: 10.1038/s41591-018-0104-9
|
[4] |
PEREIRA S, CLINE D L, GLAVAS M M, et al. Tissue-specific effects of leptin on glucose and lipid metabolism[J]. Endocr Rev, 2021, 42(1): 1-28. doi: 10.1210/endrev/bnaa027
|
[5] |
SETH M, BISWAS R, GANGULY S, et al. Leptin and obesity[J]. Physiol Int, 2020, 107(4): 455-468.
|
[6] |
GUZZARDI M A, GUIDUCCI L, CAMPANI D, et al. Leptin resistance before and after obesity: evidence that tissue glucose uptake underlies adipocyte enlargement and liver steatosis/steatohepatitis in Zucker rats from early-life stages[J]. Int J Obes (Lond), 2022, 46(1): 50-58. doi: 10.1038/s41366-021-00941-z
|
[7] |
PETRESCU M, VLAICU S I, CIUMǍRNEAN L, et al. Chronic inflammation-a link between nonalcoholic fatty liver disease (NAFLD) and dysfunctional adipose tissue[J]. Medicina (Kaunas), 2022, 58(5): 641. doi: 10.3390/medicina58050641
|
[8] |
中国肥胖问题工作组. 中国学龄儿童青少年超重、肥胖筛查体重指数值分类标准[J]. 中华流行病学杂志, 2004, 25(2): 97-102. doi: 10.3760/j.issn:0254-6450.2004.02.003
China Working Group on Obesity. Body mass index reference norm for screening overweight and obesity in Chinese children and adolescents[J]. Chinese Journal of Epidemiology, 2004, 25(2): 97-102. doi: 10.3760/j.issn:0254-6450.2004.02.003
|
[9] |
中华医学会儿科分会内分泌遗传代谢学组. 儿童非酒精性脂肪肝病诊断与治疗专家共识[J]. 中国实用儿科杂志, 2018, 33(7): 487-491.
Endocrinology, Genetics and Metabolism Group, Pefiatric Society, Chinese Medical Association. Expert consensus on the diagnosis and treatment of nonalcoholic fatty liver disease in children[J]. Chinese Journal of Practical Pediatrics, 2018, 33(7): 487-491.
|
[10] |
CHAO H W, CHAO S W, LIN H, et al. Homeostasis of glucose and lipid in non-alcoholic fatty liver disease[J]. Int J Mol Sci, 2019, 20(2): 298. doi: 10.3390/ijms20020298
|
[11] |
王声翰, 杨菊红, 郑妙艳, 等. 可溶性CD36与2型糖尿病及其并发症的关系[J]. 中华全科医学, 2020, 18(11): 1921-1924. doi: 10.16766/j.cnki.issn.1674-4152.001654
WANG S H, YANG J H, ZHENG M Y, et al. Association of soluble CD36 with type 2 diabetes and its complications[J]. Chinese Journal of General Practice, 2020, 18(11): 1921-1924. doi: 10.16766/j.cnki.issn.1674-4152.001654
|
[12] |
LEWIS G F, CARPENTIER A C, PEREIRA S, et al. Direct and indirect control of hepatic glucose production by insulin[J]. Cell Metab, 2021, 33(4): 709-720. doi: 10.1016/j.cmet.2021.03.007
|
[13] |
SHEKA A C, ADEYI O, THOMPSON J, et al. Nonalcoholic steatohepatitis: a review[J]. JAMA, 2020, 323(12): 1175-1183. doi: 10.1001/jama.2020.2298
|
[14] |
SCHWIMMER J B, JOHNSON J S, ANGELES J E, et al. Microbiome signatures associated with steatohepatitis and moderate to severe fibrosis in children with nonalcoholic fatty liver disease[J]. Gastroenterology, 2019, 157(4): 1109-1122. doi: 10.1053/j.gastro.2019.06.028
|
[15] |
BERNDT N, HUDERT C A, ECKSTEIN J, et al. Alterations of central liver metabolism of pediatric patients with non-alcoholic fatty liver disease[J]. Int J Mol Sci, 2022, 23(19): 11072. doi: 10.3390/ijms231911072
|
[16] |
李婧, 李小凤, 闫妮, 等. 评估肥胖相关指标对非酒精性脂肪肝的筛查价值[J]. 中华全科医学, 2023, 21(2): 195-198. doi: 10.16766/j.cnki.issn.1674-4152.002843
LI J, LI X F, YAN N, et al. Evaluation the screening value of obesity-related indices for non-alcoholic fatty liver disease[J]. Chinese Journal of General Practice, 2023, 21(2): 195-198. doi: 10.16766/j.cnki.issn.1674-4152.002843
|
[17] |
VATIER C, JÉRU I, FELLAHI S, et al. Leptin, adiponectin, lipodystrophic and severe insulin resistance syndromes[J]. Ann Biol Clin (Paris), 2020, 78(3): 261-264.
|
[18] |
BRAND C, GAYA A, DIAS A F, et al. Relationship between insulin resistance and adipocytokines: the mediator role of adiposity in children[J]. Ann Hum Biol, 2020, 47(3): 244-249. doi: 10.1080/03014460.2020.1740320
|
[19] |
KADO T, NAWAZ A, TAKIKAWA A, et al. Linkage of CD8+ T cell exhaustion with high-fat diet-induced tumourigenesis[J]. Sci Rep, 2019, 9(1): 12284. doi: 10.1038/s41598-019-48678-0
|
[20] |
MICU E S, AMZOLINI A M, BARǍU ABU-ALHIJA A, et al. Systemic and adipose tissue inflammation in NASH: correlations with histopathological aspects[J]. Rom J Morphol Embryol, 2021, 62(2): 509-515.
|
[21] |
DUDEK M, PFISTER D, DONAKONDA S, et al. Auto-aggressive CXCR6+ CD8 T cells cause liver immune pathology in NASH[J]. Nature, 2021, 592(7854): 444-449. doi: 10.1038/s41586-021-03233-8
|
[22] |
LEE J K, HA J H, KIM D K, et al. Depletion of zinc causes osteoblast apoptosis with elevation of leptin secretion and phosphorylation of JAK2/STAT3[J]. Nutrients, 2022, 15(1): 77. doi: 10.3390/nu15010077
|
[23] |
OSINSKI V, BAUKNIGHT D K, DASA S, et al. In vivo liposomal delivery of PPARα/γ dual agonist tesaglitazar in a model of obesity enriches macrophage targeting and limits liver and kidney drug effects[J]. Theranostics, 2020, 10(2): 585-601. doi: 10.7150/thno.36572
|